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Background: Podoconiosis, lymphatic filariasis (LF) and leprosy are neglected tropical diseases (NTDs) that cause
lymphoedema. When left untreated, they lead to substantial disability. This study determined the quality of life
(QOL) and depression associated with lymphoedema in patients with podoconiosis, LF and leprosy. The study
was conducted in northwestern Ethiopia.
Methods: This baseline cross-sectional study, nested within an interventional, non-comparative, longitudinal
study, included patients with lymphoedema. Depression and QOL were assessed using versions of the 9-item
Patient Health Questionnaire and Dermatologic Life Quality Index (DLQI), respectively, that had been translated
into Amharic and validated. Factors associated with depression and QOL were assessed usingmultivariate linear
regression analysis.
Results: Of the 251 patients with lymphoedema included in the study, 119 (47.4%) had moderate to severe
depression and overall QOL was poor (mean±standard deviation [SD] DLQI score: 11.4±4.2). Disability was sig-
nificantly associated with depression (β=0.26 [95% confidence interval {CI} 0.19 to 0.33]). Currently receiving
treatment (β=−3.05 [95% CI−5.25 to−0.85), disability (β=−0.08 [95% CI−0.15 to−0.01]) and social support
(moderate support: β=−2.27 [95% CI −3.66 to −0.89] and strong support: β=−2.87 [95% CI −5.35 to −0.38])
were significantly associated with better QOL.
Conclusion:High levels of depression and lowQOLwere found among patients with lymphoedemadue the three
NTDs in Ethiopia.
Keywords: depression, leprosy, lymphatic filariasis (LF), lymphoedema, podoconiosis, quality of life
Introduction
Lymphoedema is a chronic condition that affects the lymphatic
system and manifests as swelling of body tissues, most fre-
quently the legs and arms. In the tropics, lymphoedema is princi-
pally caused by podoconiosis, lymphatic filariasis (LF) and leprosy,
which are neglected tropical diseases (NTDs).1 NTDs are primarily
diseases of rural and some urban poor communities where there
is usually a lack of access to basic healthcare services.2
Podoconiosis mainly affects barefoot farmers in tropical
Africa, but it is also endemic in parts of Latin America and
India.3 Podoconiosis arises as a result of interaction between
environmental factors and genetic predisposition.4 Mineral parti-
cles from red clay soil are thought to induce macrophage activa-
tion and fibrosis, leading to lymphostasis, lymphatic obstruction
and then progressive lymphoedema.5 Recurrent adenolymphan-
gitis (ADL) is both a consequence of lymphoedema and a risk fac-
tor for the progression of lymphoedema. In Ethiopia, podoconio-
sis is endemic in 345 of 775 surveyed districts and is estimated
to affect 1.5 million people with 34.9 million people at risk of the
disease.6
The main clinical manifestations of LF are chronic lym-
phoedema of the legs or arms and hydrocele.7 Similar to podoco-
niosis, recurrent ADL is a risk factor for lymphoedema in patients
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access
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Figure 1. Map of Ethiopia, Amhara Region, including Guagsa Shikudad District (Gusha cluster) in the Awi Zone.
with LF. LF is reported throughout the tropics, with the high-
est prevalence in Brazil and India and including East/Southeast
Asia, Oceania and other parts of Africa and South America. It
is estimated that globally there are 67.88 million cases of LF,
including 36.45 million microfilaria carriers, 19.43 million hydro-
cele cases and 16.68 million lymphoedema cases.8 In Ethiopia,
LF is endemic in 70 districts, with >5.9 million people at risk of
acquiring the disease.9
Leprosy mainly affects the limbs, skin, peripheral nerves and
eyes.10 In 2018 there were 184 212 cases globally on multidrug
therapy, with a registered prevalence of 0.24 per 10 000 popu-
lation.11 In the same calendar year, 22 countries reported new
cases and nearly 11 323 new leprosy cases presented with grade
II disability at the time of diagnosis.11 Grade I indicates loss of
sensation but no visible deformity, while grade II disability implies
there is visible damage or deformity.
Themajority of caseswere from the Southeast Asia region and
Latin America.11 In Ethiopia, in 2015, there were 3758 new lep-
rosy cases, ofwhich 12.8%were children.Moreover, 10.2%of new
cases of leprosy had grade II disability at diagnosis.12
The objective of this study was to characterize the baseline
depression and quality of life (QOL) of people with lymphoedema
due to podoconiosis, LF or leprosy in Ethiopia prior to assessment
of the impact of an integrated holistic physical,mental health and
psychosocial care package. Specifically, the study aims were to
determine the prevalence of depression among people with lym-
phoedema due to podoconiosis, LF or leprosy; measure the QOL
among people with lymphoedema caused by podoconiosis, LF or
leprosy; and determine the sociodemographic factors that con-
tribute to depression and QOL in this population.
Methods
Study description
The ‘parent’ study from which the data were derived, the Excel-
lence in Disability Prevention Integrated across NTDs (EnDPoINT)
project, has three phases: in phase 1, a holistic care package
involving physical, mental health and psychosocial care was
developed; in phase 2 the care packagewas piloted in one subdis-
trict; then, based on the findings of phase 2, phase 3 will scale up
the care package in three districts. The data analysed here origi-
nate from phase 2 of the parent study, which also corresponds
to phase 2 of the framework on complex interventions of the
United Kingdom’s Medical Research Council (MRC).13 According
to this MRC framework, phase 1 is development of the package,
phase 2 is feasibility piloting, phase 3 is evaluation and phase 4
is implementation. The phase 2 study was conducted in Gusha
Health Centre, in one cluster of Guagusa Shikudad District (Gusha
cluster), in Awi Zone, Amhara Region, northwestern Ethiopia. In a
cluster there are five kebeles (subdistricts) and one health centre
serving approximately 25 000 people.
Study design
A longitudinal non-comparative study was conducted. After
baseline data collection, the holistic package of physical, men-
tal health and psychosocial care was implemented. Data were
collected at the 3-month follow-up and we hope to collect data
at 12 months. Here we report on the baseline depression and
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Ethical approval was obtained from the Research Governance
and Ethics Committee (RGEC) of the Brighton & Sussex Med-
ical School (reference number: ER/BSMS9D79/2) and the Col-
lege of Health Sciences, Addis Ababa University Institutional
Review Board (IRB) (reference number: 061/18/CDT). Written
informed consent was obtained from study participants, who
were informed that they were free to withdraw from the study
at any stage.
Study area and population
The study was conducted in the Gusha cluster of the Awi Zone,
which is divided into seven districts and is one of 10 zones of the
Amhara Region, northwestern Ethiopia (Figure 1). This zone was
selected as it is co-endemic for the three NTDs of interest and,
to date, few interventions addressing these diseases have been
implemented there.
Adults (≥18 y of age) with lower limb lymphoedema caused
by LF, podoconiosis and/or leprosy were identified by community
health extension workers during routine home visits and linked
with Gusha Health Centre. Patients who gave their informed
consent were eligible for inclusion in the study. Patients were
excluded from the study if they expected to leave the study site
during the study period, had nodular disease preventing the use
of shoes (these individuals were referred for nodulectomy) or had
complex wounds (these individuals were referred for specialist
care in Injibara Hospital).
Data collection and management
Experienced data collectors were recruited and trained on how
to use the study tools and how to extract information from both
written and electronic health records. These trained community
data collectors administered the validated questionnaires that
had been translated into the local language of Amharic.
Regular supervision of the data collection process was carried
out by the investigating team. Onsite supervision and feedback
were given to the data collectors. All completed questionnaires
and tools were checked for consistency, completeness, clarity
and accuracy. Data were collected by smartphone using Open
Data Kit, free software developed to allow data collection using
Android mobile devices and data submission to an online server.
After collection, data were transferred to an Excel (Microsoft,
Redmond, WA, USA) data sheet for cleaning and verification,
before being exported to Stata version 14 (StataCorp, College Sta-
tion, TX, USA) for analysis.
Patient demographics (sex, age) and socio-economic charac-
teristics (residence, education level, marital status, children, reli-
gion, employment status and relative income) were recorded at
baseline using a pretested structured questionnaire.
The following physical and clinical characteristics were also
measured using a validated questionnaire: history and frequency
of acute attacks of lymphoedema and degree of disability. In
addition, the following psychosocial outcomes were assessed:
QOL, alcohol use disorder, social support and mental health con-
dition of the participants, including depression, suicidal ideation
and attempted suicide.
Table 1. Demographics and socio-economic characteristics of








Age (years), mean (range) 51.9 (18–88)










Marital status, n (%)




Religion, Christian, n (%) 251 (100)





Not working 4 (1.6)
Othera 2 (0.8)
Relative income, n (%)




Have children, n (%)
Yes 223 (88.8)
No 28 (11.2)
Percentages may not add up to 100 due to rounding.
aOne daily labourer and one unable work due to disability.
Assessment tools
We have read recent discussions about assessment tools of QOL
in lymphoedema14,15 and have chosen the Dermatology Life
Quality Index (DLQI) as suitable for our purpose.
QOL was assessed using the DLQI.16 It consists of 10 ques-
tions covering several dimensions of life quality, including pain,
embarrassment, interferencewith activities of daily life and social
and sexual relationships. LowDLQI scores suggest highQOL. DLQI
has been used in patients with filarial lymphoedema in Guyana17
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Table 2. Clinical characteristics of patients with lymphoedema participating in the study (N=251)
Variables Values
Type of case with lymphoedema, n (%)
Lymphatic filariasis/podoconiosis 246 (98.0)
Leprosy 5 (2.0)
Has your leg ever suddenly become hot, red and painful? (i.e. an acute attack), n (%)
Yes 235 (93.6)
No 16 (6.4)
How often does your leg become hot, red and painful? (i.e. acute attack), n (%) (N=235)
Every week 62 (26.4)
Every 2 weeks 58 (24.7)
Every month 48 (20.4)
Every 3 months 31 (13.2)
Every 6 months 19 (8.1)
Every year 11 (4.7)
≥1 y 6 (2.6)
Number of acute episodes in the month prior to the survey, mean±SD (range) 2.4 ± 2.6 (0–20)
Have you ever received treatment for your leg lymphoedema?, n (%)
Yes 39 (15.5)
No 212 (84.5)
Are you currently receiving treatment for, or self-treating your leg(s)?, n (%)
Yes 21 (8.4)
No 230 (91.6)
Where did you receive/are you receiving treatment?, n (%) (N=39)
Government clinic 27 (69.2)
Non-government clinic 6 (15.4)
Self-treatment 4 (10.3)
Traditional healer 1 (2.6)
Other 1 (2.6)
Percentages may not add up to 100 due to rounding.
official Ethiopian language, Amharic,19 and used to assess QOL
in podoconiosis patients in southern Ethiopia.
Disability was measured using the World Health Organization
Disability Assessment Schedule tool (the 12-item WHODAS ver-
sion 2.0).20 The WHODAS was developed to measure disability
and to assess the following: standing for long periods (e.g.
30 min), taking care of household responsibilities, learning a new
task, joining community activities, effect of health problems on
emotions, concentrating for 10 min, walking a long distance
(1 km or equivalent), getting dressed, maintaining a friend-
ship and maintaining day-to-day work. It has been translated
into Amharic and used to assess disability due severe mental
disorders in rural Ethiopia.21
Depression was assessed using the 9-item Patient Health
Questionnaire (PHQ-9).22 It is a widely used depression screening
scale for primary healthcare settings in high-income coun-
tries and has also been validated in low- and middle-income
countries (LMICs).23 The nine items of the PHQ follow the Diag-
nostic and Statistical Manual (DSM) version IV diagnostic criteria
for a depressive episode. Each question requires participants
to rate the frequency of a depressive symptom experienced
in the 2 weeks prior to evaluation. These items include little
interest or pleasure in doing things, depressed mood, insom-
nia or hypersomnia, fatigue, appetite disturbances, guilt or
worthlessness, diminished ability to concentrate, psychomotor
agitation and suicidal thoughts. The total PHQ-9 score ranges
from 0 to 27.22 In Ethiopia it has been translated into Amharic
and used to detect depression in primary care settings.24,25
Alcohol use disorder was evaluated using the Fast Alcohol
Screening Test (FAST).26 It is derived from the Alcohol Use Dis-
order Identification Test (AUDIT) and can be easily administered
in 1 min. The items in FAST include: How often do you have eight
or more drinks (six or more drinks for women) on one occasion?
In the past year, how often have you been unable to remember
what happened the night before because you had been drinking?
Have you failed do what was normally expected of you because
of drinking? Has a relative or friend, or a doctor or other health
worker, been concerned about your drinking or suggested you
cut down? The score ranges from 0 (never) to 4 (daily or almost
daily). A score ≥3 out of 16 indicates hazardous alcohol use, a
form of drinking that is related to increased risk of adverse psy-
chological or physical consequences in the future.27,28 The FAST
has also been translated into Amharic and used in assessing the
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Table 3. Mental health and psychosocial characteristics of patients with lymphoedema participating in the study (N=251)
Variables Values
Depressive symptoms (based on PHQ-9 score <5), n (%)
Not depressed 34 (13.5)
Depressed 217 (86.5)
Level of depressive symptoms (based on PHQ-9 score), n (%)
No depression (0–4) 34 (13.5)
Mild (5–9) 98 (39.0)
Moderate (10–14) 75 (29.9)
Moderately severe (15–19) 28 (11.2)
Severe (20–27) 16 (6.4)
Alcohol use disorder (based on FAST), n (%)
No alcohol use disorder 159 (63.4)
Alcohol use disorder 92 (36.7)




Disability measure (based on WHODAS), mean±SD
WHODAS score 29.6 ± 8.8 (median 28.0)
How many days in the past 30 d have these difficulties been present? 12.4 ± 6.2
How many days in the past 30 d were you totally unable carry out your usual activities? 6.3±4.7
How many days in the past 30 d did you cut back or reduce your usual activities? 3.7 ± 2.7
Quality of life (DLQI score), mean±SD 11.4±4.2
DLQI effect on patients’ life, n (%)
No effect (0–1) 4 (1.6)
Small (2–5) 27 (10.8)
Moderate (6–10) 77 (30.7)
Very large (11–20) 134 (53.4)
Extremely large (21–30) 9 (3.6)
DLQI subscale, mean±SD
Symptoms and feelingsa 3.4 ± 1.4
Daily activitiesa 2.3 ± 1.7
Leisurea 1.8 ± 1.4
Work and schoolb 2.4 ± 1.1
Personal relationshipsa 1.1 ± 1.3
Treatmentb 0.7 ± 0.9
Percentages may not add up to 100 due to rounding.
aMaximum value of subscale = 6.
bMaximum value of subscale = 3.
psychometric properties, with sensitivity of 93% and specificity of
88%,27 which is comparable to theAUDIT.30 Local alcoholic bever-
ages were converted into standard equivalent alcohol units when
reported by the respondents using different containers such as
flasks, cans and glasses.
Suicidal ideation and suicide attempts were measured using
the Composite International Diagnostic Interview (CIDI) scale.
There are four main questions: During the past 1 month: Did
you think a lot about death?; Did you feel so low you thought a
lot about committing suicide?; Did you make a plan as to how
you might do it?; Did you attempt suicide?31 This CIDI has been
used to measure suicidal ideation and suicide attempts among
human immunodeficiency virus (HIV)-infected individuals.32 The
CIDI was also used in studies in the community and primary
health facilities in LMICs, including Ethiopia, with the study aim of
determining the 12-month prevalence of suicidal ideation, plans
and attempts, as well as associated risk factors.31
Social support was measured using the Oslo Social Support
tool (Oslo-3),33 a very brief scale that assesses the number of
close confidantes, perceived level of concern from others and
perceived ease of getting help from neighbours. The total score
ranges from 3 to 14 and higher scores represent better social
support. The scores can be categorized in three levels: 3–8, poor
social support; 9–11, moderate social support; and 12–14, strong
social support.33 The internal consistency in a population based
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Table 4. Suicidal ideation and suicide attempts, assessed using the CIDI, among patients with lymphoedema participating in the study (N=251)
Variables Values
Suicidal ideation in the last month, n (%)
Yes 31 (12.4)
No 220 (87.6)
Suicide planning in the last month, n (%)
Yes 23 (9.2)
No 228 (90.8)
Suicide attempts in the last month, n (%)
Yes 19 (7.6)
No 232 (92.4)
Among those who attempted suicide (N=19), frequency of attempt, mean±SD (range) 1.9 ± 0.9 (1–5)
Received any treatment for thinking about or attempting to take your own life?, n (%)
Yes 0
No 31 (100)
Percentages may not add up to 100 due to rounding.
scale is very brief with only three items.33 The Oslo-3 scale has
been used in Ethiopia in a study that examined the prevalence
of and factors associated with depression among patients with
HIV/acquired immunodeficiency syndrome (AIDS),34 as well as
a study addressing the prevalence and predictors of depression
among pregnant women.35
Data analysis
Descriptive analysis was performed for sociodemographic fac-
tors, clinical and psychosocial explanatory factors and outcome
variables.
Depression (measured using the PHQ-9) and QOL (measured
using DLQI) were the primary outcome measures. There are four
categories of depression, based on severity, using PHQ-9 cut-
offs: <5, no depression; 5–9, mild depression; 10–14, moderate
depression; 15–19, moderately severe depression; and 20–27,
severe depression.22 For diagnosis of depression, PHQ-9 with a
cut-off of 10 has shown good sensitivity and specificity, however,
a cut-off of 5 had lower sensitivity and specificity.25 The best DLQI
score is 0 and the worst score is 30.16
Linear regression analysis was used to examine the associa-
tion between explanatory variables and depression measured by
the PHQ-9 and QOL measured by DLQI. For both the PHQ-9 and
DLQI, explanatory variables with an association of p < 0.2 in the
bivariate analysis were included in the multivariate linear regres-
sion model. In the multivariate linear regression model, those
explanatory variables with association at p<0.05 were consid-
ered statistically significant.
Results
Demographics and socio-economic characteristics
at baseline
A total of 251 patients with lymphoedema associated with LF,
podoconiosis or leprosy were included in the study. Their mean
age was 51.9 y (range 18–88) (Table 1). Among the study par-
ticipants, 52.6% were female, 99.6% lived in a rural area, 66.2%
were illiterate, 67.7% were married, all were Orthodox Christians
and 77.3% were farmers (Table 1).
Clinical and psychosocial characteristics at baseline
Among the study population, 93.6%had a history of acute attack.
The mean±standard deviation (SD) number of acute attacks in
the month prior to the survey was 2.4 ± 2.6. Only 15.5% of par-
ticipants had ever received treatment for their leg lymphoedema
and only 8.4% of participants were currently receiving treat-
ment or administering self-treatment at the time of enrolment
(Table 2).
The prevalence of depression with a PHQ-9 cut-off of 10 was
47.4% (119/251 participants). Considering the severity of depres-
sion, 39.0% of participants were classed as having mild depres-
sion, 29.9%moderate, 11.2%moderately severe and6.4% severe
depression (Table 3). The mean DLQI was 11.4 ± 4.2. Lym-
phoedema had a very large effect on the patient’s QOL in 53.4%
of cases and a moderate effect in 30.7% of cases (Table 3).
Assessment of other psychosocial characteristics showed that
36.6% of participants displayed a hazardous drinking habit and
65.3% had poor social support (Table 3). The mean WHODAS
score for disability was 29.6± 8.8, themean number of days over
the last 30 dwhere the personwas unable do their usual activities
or work was 6.3 ± 4.7 and the mean number of days where they
cut back or reduced their usual activities was 3.7 ± 2.7 (Table 3).
Using the CIDI scale, 12.4% of 251 study participants had sui-
cidal thoughts, 9.2% reported planning suicide and 7.6% reported
a suicide attempt (Table 4). None of the participants with suicidal
ideation had accessed any form of treatment for this (Table 4).
Factors associated with depression
In the bivariate linear regression analysis, sex, age, educational
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Table 5. Bivariate analysis using depression, assessed using the PHQ-9 scale, as a continuous outcome variable (N=251)
Variable PHQ-9 score, mean±SD β (95% CI) p-Valuea
Sex
Male 9.2 ± 5.4 −1.54 (−2.81 to −0.27) 0.02
Female (reference) 10.7 ± 4.8 1.0
Age (continuous) 10.0 ± 5.2 0.05 (0.01 to 0.08) 0.03
Education
Illiterate 10.8 ± 5.4 2.32 (1.03 to 3.62) <0.001
Literate (reference) 8.5 ± 4.4 1.0
Marital status
Currently married 9.5 ± 5.2 −1.44 (−2.81 to −0.08) 0.04
Currently not married (reference) 10.9 ± 5.0 1.0
Employment
Employedb 10.2 ± 5.5 0.90 (−0.71 to 2.42) 0.28
Not employed (reference) 9.3 ± 3.20 1.0
Relative income
Very low and low (reference) 11.3 ± 5.3 1.0 <0.001
Middle and high 8.2 ± 4.4 −3.11 (−4.35 to −1.87)
Acute attack frequency (N=235)
Every week/2 weeks/month (reference) 10.2 ± 5.1 1.0
≥3 months 9.3 ± 5.1 −0.92 (−2.39 to 0.53) 0.21
Acute attack (continuous) 10.0 ± 5.2 0.01 (−0.24 to 0.26) 0.93
Have you ever received treatment for your leg lymphoedema?
No (reference) 9.8 ± 5.1 1.0 0.35
Yes 10.7 ± 5.6 0.84 (−0.93 to 2.61)
Are you currently receiving treatment for, or self-treating your leg(s)?
No (reference) 10.0 ± 5.1 1.0 0.82
Yes 9.7 ± 5.9 −0.27 (−2.59 to 2.05)
Hazardous drinking habit (FAST)
No (reference) 9.7 ± 4.9 1.0 0.38
Yes 10.3 ± 5.5 0.60 (−0.74 to 1.93)
Social support (based on Oslo-3)
Poor (reference) 5.9 ± 5.2 1.0
Moderate 9.0 ± 4.9 −1.76 (−3.17 to −0.35) 0.01
Strong 10.8 ± 3.5 −4.85 (−7.29 to −2.41) <0.001
Disability assessment based on WHODAS (continuous) 11.8 ± 5.1 0.31 (0.25 to 0.37) <0.001
DLQI (continuous) 10.0 ± 5.2 −0.04 (−0.17 to 0.09) 0.52
aLinear regression was used to examine the association between explanatory variables and depression measured by the PHQ-9. Explanatory
variables with an association of p<0.2 in the bivariate analysis were included in the multivariate linear regression model.
bSalaried, self-employed and farming.
relative income were significantly associated with depression
(Table 5). However, in the multivariate linear regression analy-
sis, none of these sociodemographic factors were significantly
associated with depression. In the multivariate linear regression
model, there was a positive, statistically significant, association
between disability, as measured by the WHODAS, and depres-
sion, as measured by the PHQ-9 (β=0.26 [95% CI 0.19 to 0.33])
(Table 6).
Factors associated with quality of life
In the bivariate linear regression analysis, none of the sociode-
mographic factors, history of acute attack or frequency of
attack in the past month were associated with QOL as
measured by the DLQI (Table 7). In the multivariate lin-
ear regression model, currently receiving treatment was sig-
nificantly associated with improved QOL (β=−3.05 [95% CI
−5.25 to −0.85]). Hazardous drinking habit was associated
with poor QOL (β=1.31 [95% CI 0.02 to 2.59]). Social sup-
port was also significantly associated with improved QOL. Using
poor social support as a reference, participants with moder-
ate social support had β=−2.27 (95% CI −3.66 to −0.89)
and those with strong social support had β=−2.87 (95%
CI −5.35 to −0.38). In addition, disability was significantly
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Table 6. Multivariate linear regression analysis using depression, assessed using the PHQ-9 scale, as a continuous outcome variable (N=251)
Variables PHQ-9, mean±SD β (95% CI) p-Valuea
Sex
Male 9.2 ± 5.4 1.0
Female 10.7 ± 4.8 0.39 (−1.02 to 1.80) 0.59
Age (continuous) 10.0 ± 5.2
Education
Illiterate 10.8 ± 5.4 1.0
Literate 8.5 ± 4.4 0.01 (−0.03 to 0.05) 0.67
Marital status
Currently married 9.5 ± 5.2 1.0
Currently not married 10.9 ± 5.0 0.07 (−1.30 to 1.43) 0.92
Relative income
Very low and low 11.3 ± 5.3 1.0
Middle and high 8.2 ± 4.4 −1.17 (−2.42 to 0.09) 0.07
Social support (based on Oslo-3)
Poor (reference) 5.9 ± 5.2 1.0
Moderate 9.0 ± 4.9 −0.83 (−2.09 to 0.41) 0.19
Strong 10.8 ± 3.5 −2.07 (−4.27 to 0.13) 0.07
Disability assessment based on WHODAS (continuous) 11.8 ± 5.1 0.26 (0.19 to 0.33) <0.001
aLinear regression was used to examine the association between explanatory variables and depression measured by the PHQ-9. Explanatory
variables with an association of p<0.2 in the bivariate analysis were included in the multivariate linear regression model. In the multivariate
linear regression model, those explanatory variables with association at p<0.05 were considered statistically significant.
Discussion
The present study demonstrated high levels of depression and
low QOL among study participants with lymphoedema asso-
ciated with LF, podoconiosis or leprosy. Disability, as assessed
by the WHODAS, was the factor most significantly associated
with depression in this population. A high proportion of patients
(47.4%) reported moderate to severe depressive symptoms. QOL
was significantly associated with current treatment, social sup-
port, alcohol use disorder and disability.
Among study participants, 12.4% had suicidal thoughts, 9.2%
reported suicidal planning and 7.6% reported suicide attempts.
This is lower than among HIV-positive individuals, among whom
the lifetime prevalence of suicidal ideation was 26% and that of
suicide attempt was 13%.32 Moreover, suicidal ideation was sig-
nificantly associated with major depressive disorder.32 A similar
prevalence of suicidal ideation (10.3%) and relatively lower rate
of suicidal planning (2.2%) was reported previously in a study
in five LMICs among community/healthcare-seeking populations
presenting at primary care facilities.31
An association between depression and lymphoedema due
to podoconiosis, LF or leprosy has also been reported by other
researchers. A comparative cross-sectional study in northern
Ethiopia showed a higher prevalence of depression, measured
using the PHQ-9 scale, amongpatientswith podoconiosis (12.6%)
compared with their apparently healthy neighbours (0.7%).36
Another cross-sectional study among people living with LF in
Nigeria, which used the PHQ-9 and CIDI to measure depres-
sion, found a higher prevalence of depression (20%) among LF-
affected individuals than the reported ‘background’ prevalence
among the general adult population in Nigeria (3.1–5.2%).37 A
study in Cameroon used the PHQ-9 scale to demonstrate a high
prevalence of depressive symptoms (38.5%) among individuals
with lower limb lymphoedema (predominantly due to podoco-
niosis), although the majority had mild depression.38 Studies on
individuals affected by leprosy have also reported a high bur-
den of depression.39,40 For example, the prevalence of psychiatric
morbidity among leprosy patients in Nigeria was found to be 58%
and most cases had depression.39
Poor socio-economic status might contribute to the high bur-
den of depression among the study participants. Only 2.4% of
study participants belong to the high relative income group in our
study. However, despite an association between relative income
and depression, this was not statistically significant (p=0.07). It
is possible that a lack of treatment for lymphoedema (as found
in 85.5% of participants) led to disease progression, which itself
may have led to depressive symptoms. Stigma and discrimina-
tion due to lymphoedemamay also have contributed to the high
prevalence of depressive symptoms.
QOL was moderately compromised in one-third of cases and
severely compromised in about half of patients in the present
study; themean DLQI scorewas high at 11.4± 4.2. Similar results
were reported in a previous intervention study from Guyana
among people affected by LF lymphoedema, showing a base-
line mean DLQI of 10.9.17 In contrast, a study from India among
LF lymphoedema cases reported a relatively low mean DLQI
value of 2.7 ± 4.4,18 indicating better QOL than was observed
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Table 7. Bivariate analysis using QOL, assessed using the DLQI as a continuous outcome variable (N=251)
Variables DLQI, mean ± SD β (95% CI) p-Valuea
Sex
Male 12.4 ± 5.3 1.24 (−0.02 to 2.49) 0.05
Female (reference) 11.2 ± 4.8 1.0
Age (continuous) 11.8 ± 5.1 −0.006 (−0.05 to 0.04) 0.76
Education
Illiterate 11.3 ± 4.9 −1.17 (−2.47 to 0.12) 0.08
Literate (reference) 12.5 ± 5.4 1.0
Marital status
Currently married 11.8 ± 5.2 0.06 (−1.29 to 1.41) 0.93
Currently not married (reference) 11.7 ± 4.8 1.0
Employment
Employedb 11.9 ± 5.1 0.82 (−0.72 to 2.37) 0.24
Not employed (reference) 11.1 ± 5.0 1.0
Relative income
Very low and low (reference) 11.8 ± 4.9 1.0
Middle and high 11.6 ± 5.3 −0.22 (−1.50 to 1.06) 0.74
Acute attack frequency (N=235)
Every week/2 weeks/month (reference) 11.8 ± 5.1 1.0
≥3 months 11.8 ± 4.9 −0.02 (−1.45 to 1.42) 0.98
Acute attack (continuous) 11.8 ± 5.1 0.07 (−0.19 to 0.31) 0.61
Have you ever received treatment for your leg lymphoedema?
No (reference) 11.9 ± 5.0 1.0
Yes 11.0 ± 5.4 −0.94 (−2.68 to 0.80) 0.29
Are you currently receiving treatment for, or self-treating your leg(s)?
No (reference) 12.0 ± 5.1 1.0
Yes 9.2 ± 4.2 −2.74 (−4.99 to −0.48) 0.02
Hazardous drinking habit (FAST)
No (reference) 11.3 ± 5.2 1.0
Yes 12.5 ± 4.8 1.21(−0.09 to 2.51) 0.07
Social support (based on Oslo-3)
Poor (reference) 12.4 ± 4.7 1.0
Moderate 10.5 ± 5.2 −1.93 (−3.35 to −0.52) 0.008
Strong 10.7 ± 7.2 −1.67 (−4.13 to 0.78) 0.18
Disability assessment based on WHODAS (continuous) 11.8 ± 5.1 −0.06 (−0.13 to 0.01) 0.11
PHQ-9 (continuous) 11.8 ± 5.1 −0.04 (−0.16 to 0.08) 0.52
aLinear regression was used to examine the association between explanatory variables and quality of life measured by DLQI. Explanatory
variables with an association of p<0.2 in the bivariate analysis were included in the multivariate linear regression model.
bSalaried, self-employed and farming.
the World Health Organization Quality of Life Brief Version ques-
tionnaire (WHOQoL-BREF) and found that people with podoco-
niosis had significantly poorer QOL than controls.41 In a study
in Bangladesh, the WHOQoL-BREF score was lower among peo-
ple affected by leprosy than controls.42 A cross-sectional study
in Brazil among leprosy-affected individuals also reported low
WHOQoL-BREF scores.43 Here we demonstrated that patients
currently on treatment had a better QOL than those who were
not, implying that emphasis should be given to early diagnosis
and management of cases.
The only factor significantly associated with depression
among people with lymphoedema was higher disability score.
Similarly, a study from northern Ethiopia among patients with
podoconiosis showed that increased disability, as measured by
the WHODAS, was associated with increased depression among
patients with podoconiosis.36 A study conducted in Bangladesh
on leprosy-affected individuals also showed a significant asso-
ciation between disability, as measured by the WHO disability
grade, and depression as measured by the Centre for Epidemi-
ologic Studies Depression Scale.40
Disability was inversely related to QOL, i.e. lower disability
scores were associated with higher QOL. This suggests that pre-
vention of disability due lymphoedemamay also prevent depres-
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Table 8. Multivariate linear regression analysis using QOL assessed using the DLQI as a continuous outcome variable (N=251)
Variables DLQI, mean±SD β (95% CI) p-Valuea
Sex
Male 12.4 ± 5.3 −1.0 (−2.34 to 0.36) 0.15
Female (reference) 11.2 ± 4.8 1.0
Education
Illiterate 11.3 ± 4.9 0.75 (−0.64 to 2.14) 0.29
Literate (reference) 12.5 ± 5.4 1.0
Are you currently receiving treatment for, or self-treating your leg(s)?
No (reference) 12.0 ± 5.1 1.0
Yes 9.2 ± 4.2 −3.05 (−5.25 to −0.85) 0.007
Hazardous drinking habit (FAST)
No (reference) 11.3 ± 5.2 1.0
Yes 12.5 ± 4.8 1.31 (0.02 to 2.59) 0.046
Social support (based on Oslo-3)
Poor (reference) 12.4 ± 4.7 1.0
Moderate 10.5 ± 5.2 −2.27 (−3.66 to −0.89) 0.001
Strong 10.7 ± 7.2 −2.87 (−5.35 to −0.38) 0.024
Disability assessment based on WHODAS (continuous) 11.8 ± 5.1 −0.08 (−0.15 to −0.01) 0.035
aLinear regression was used to examine the association between explanatory variables and quality of life measured by DLQI. Explanatory
variables with an association of p<0.2 in the bivariate analysis were included in the multivariate linear regression model. In the multivariate
linear regression model, those explanatory variables with association at p<0.05 were considered statistically significant.
positively associated with low QOL, while study participants with
better social support had better QOL. Similar results have been
reported in previous studies. A study in Iran among people liv-
ing with HIV showed a significant association between QOL, as
measured by the 36-item Short-Form Health Survey (SF-36), and
social support.44 There was an association between QOL, asmea-
sured by the WHOQOL-BREF, and social support in a study on
hospitalized schizophrenia patients in Malaysia,45 while disabil-
ity was inversely related to QOL and improvement in disability
was associated with improved QOL. Disability, measured using
theWHODAS,was significantly associatedwithQOL,measured by
the SF-36, in study participants with mental disorder46 and QOL,
assessed by theWHOQOL-BREF, was significantly associatedwith
disability among leprosy patients in northeastern Brazil.43
There were some limitations to the current study. First, the
study design was cross-sectional in nature, making it difficult to
determine a direction of association between presumed explana-
tory variables and depression or QOL. Second, although most of
the tools, including the PHQ-9, DLQI andWHODAS, have been val-
idated in Ethiopia, despite their use in studies in other parts of the
world, the FAST and Oslo-3 have not been validated in Ethiopia.
Third, we did not measure all factors that might be associated
with depression e.g. family history of mental illness, wealth index
or comorbidities or factors that might affect QOL, such as wealth
index and comorbidities.
Conclusions
Our findings indicate a considerable burden of depression and
poor QOL among study participants with lymphoedema due
podoconiosis, LF or leprosy. Therefore a holistic package of care
that addresses the physical, mental, social and psychological
needs of people with lymphoedema is warranted. Interventions
targeting morbidity management and disability prevention of
these three NTDs should integrate best practices in addressing
the mental, social and psychological aspects of these diseases.
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